Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Sell

Analyst Rating

Neutral

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Buy

A

Akero Therapeutics, Inc. Common Stock (AKRO)

Pharmaceutical Preparations

https://www.akerotx.com

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

601 GATEWAY BOULEVARD, SUITE 350
SOUTH SAN FRANCISCO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

06/20/2019

Market Cap

1,729,174,074

Shares Outstanding

55,710,000

Weighted SO

55,709,783

Total Employees

N/A

Upcoming Earnings

08/09/2024

Similar Tickers

TERN --.--%

MDGL --.--%

INZY --.--%

VKTX --.--%

ICPT --.--%

RETA --.--%

RVMD --.--%

RNA --.--%

PTGX --.--%

Beta

-0.2820

Last Div

0.0000

Range

11.25-53.77

Chg

0.5850

Avg Vol

791300

Mkt Cap

1729174074

Exch

NASDAQ

Country

US

Phone

650 487 6488

DCF Diff

21.0601

DCF

3.9599

Div Yield

0.0000

P/S

6088.6411

EV Multiple

-6.4290

P/FV

2.1583

Div Yield %

0.0000

P/E

-8.4361

PEG

2.3537

Payout

-1.6498

Current Ratio

24.8929

Quick Ratio

24.8929

Cash Ratio

9.9556

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

590813.3333

CCC

-590813.3333

Gross Margin

0.9683

Op Margin

-824.5880

Pretax Margin

-718.9296

Net Margin

-718.9296

Eff Tax Rate

0.0188

ROA

-0.2360

ROE

-0.2956

ROCE

-0.2808

NI/EBT

1.0000

EBT/EBIT

0.8719

EBIT/Rev

-824.5880

Debt Ratio

0.0411

D/E

0.0446

LT Debt/Cap

0.0420

Total Debt/Cap

0.0427

Int Coverage

-151.5748

CF/Debt

-5.3653

Equity Multi

1.0839

Rec Turnover

0.0000

Pay Turnover

0.0006

Inv Turnover

0.0000

FA Turnover

0.3156

Asset Turnover

0.0003

OCF/Share

-2.7608

FCF/Share

-2.7608

Cash/Share

10.9917

OCF/Sales

-672.3204

FCF/OCF

1.0000

CF Coverage

-5.3653

ST Coverage

-303.5596

CapEx Coverage

0.0000

Div&CapEx Cov

-0.5668

P/BV

2.1583

P/B

2.1583

P/S

6088.6411

P/E

-8.4361

P/FCF

-9.0562

P/OCF

-9.0209

P/CF

-9.0209

PEG

2.3537

P/S

6088.6411

EV Multiple

-6.4290

P/FV

2.1583

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. May 10, 16:28 Akero Therapeutics präsentiert auf dem EASL-Kongress 2025 die Ergebnisse nach 96 Wochen der klinischen Phase-IIb-Studie SYMMETRY zu Efruxifermin bei Patienten mit kompensierter Zirrhose, die durch MASH verursacht wird, und zeigt eine Verbesserung der Fibr GlobeNewswire Inc. May 10, 16:28 Akero Therapeutics présente les résultats de la 96e semaine de l’essai clinique de phase 2b SYMMETRY sur l’éfruxifermine chez des patients atteints de cirrhose compensée causée par une stéatohépatite associée à un dysfonctionnement métabolique (MASH), mon GlobeNewswire Inc. May 10, 14:28 Akero Therapeutics gibt Publikation von „Phase IIb SYMMETRY“-Studie im New England Journal of Medicine bekannt GlobeNewswire Inc. May 10, 14:28 Akero Therapeutics annonce la publication de l’essai de phase 2b SYMMETRY dans le New England Journal of Medicine GlobeNewswire Inc. May 10, 14:00 Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025 GlobeNewswire Inc. Apr 07, 21:59 INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm The Motley Fool Feb 02, 23:21 This Stock Just Doubled in 1 Day -- Is It Still a Buy? GlobeNewswire Inc. Jan 29, 02:30 Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Investing.com Jul 19, 02:21 Akero Therapeutics CFO sells over $976k in company stock - Investing.com Seeking Alpha Nov 20, 00:24 Buy These Stocks; Members Of The Most Hated Tech Sector

Revenue Product Segmentation